Published in Legal

Bausch + Lomb to purchase AcuFocus

This is editorially independent content
2 min read

Bausch + Lomb Corporation announced that an affiliate of the company has acquired AcuFocus, pursuant to a merger transaction with its parent company .

Tell me more about AcuFocus

AcuFocus, Inc is a privately-held ophthalmic medical device company that delivers breakthrough small aperture intraocular products to address diverse unmet needs in eye care and help patients achieve their best personal vision. (via)

Any notable technology included in this purchase?

Yes! AcuFocus’s IC-8 Apthera intraocular lens (IOL) was approved in July 2022 as the first and only small-aperture, non-toric extended-depth-of-focus (EDOF) IOL for unilateral implantation indicated for monovision.

The presbyopia-correcting IOL is intended to treat cataract patients with as much as a 1.5 diopters of corneal astigmatism with a potential benefit of monofocal-like binocular contrast sensitivity which could enhance adaptability through its novel wavefront-filtering design. The company announced that the first commercial patients were implanted with the IOL via cataract surgery in the U.S. earlier this month. (via)

What does this mean for Bausch + Lomb?

Bausch + Lomb’s CEO Joseph C. Papa noted that the addition of the IC-8 Apthera EDOF IOL will bolster the company’s surgical profile by enhancing its IOL profile—a strategic area of focus for the company.

When is the deal effective?

The terms of the transaction were not disclosed, so stay tuned!